BRPI1013376A8 - tratamento de neuropata ótica hereditária de leber e atrofia ótica dominante com quinonas de tocotrienol. - Google Patents

tratamento de neuropata ótica hereditária de leber e atrofia ótica dominante com quinonas de tocotrienol.

Info

Publication number
BRPI1013376A8
BRPI1013376A8 BRPI1013376A BRPI1013376A BRPI1013376A8 BR PI1013376 A8 BRPI1013376 A8 BR PI1013376A8 BR PI1013376 A BRPI1013376 A BR PI1013376A BR PI1013376 A BRPI1013376 A BR PI1013376A BR PI1013376 A8 BRPI1013376 A8 BR PI1013376A8
Authority
BR
Brazil
Prior art keywords
leber
treatment
dominant
tocotrienol quinones
hereditary
Prior art date
Application number
BRPI1013376A
Other languages
English (en)
Portuguese (pt)
Inventor
M Miller Guy
Original Assignee
Bioelectron Tech Corp
Edison Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelectron Tech Corp, Edison Pharmaceuticals Inc filed Critical Bioelectron Tech Corp
Publication of BRPI1013376A2 publication Critical patent/BRPI1013376A2/pt
Publication of BRPI1013376A8 publication Critical patent/BRPI1013376A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1013376A 2009-04-28 2010-04-27 tratamento de neuropata ótica hereditária de leber e atrofia ótica dominante com quinonas de tocotrienol. BRPI1013376A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21479509P 2009-04-28 2009-04-28
US31873310P 2010-03-29 2010-03-29
PCT/US2010/032624 WO2010126911A1 (en) 2009-04-28 2010-04-27 Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones

Publications (2)

Publication Number Publication Date
BRPI1013376A2 BRPI1013376A2 (pt) 2017-03-21
BRPI1013376A8 true BRPI1013376A8 (pt) 2018-01-09

Family

ID=42244195

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013376A BRPI1013376A8 (pt) 2009-04-28 2010-04-27 tratamento de neuropata ótica hereditária de leber e atrofia ótica dominante com quinonas de tocotrienol.

Country Status (15)

Country Link
US (3) US20100273894A1 (enExample)
EP (2) EP2424495B1 (enExample)
JP (3) JP2012525399A (enExample)
BR (1) BRPI1013376A8 (enExample)
CA (1) CA2777479C (enExample)
DK (1) DK2424495T3 (enExample)
EA (1) EA031126B1 (enExample)
ES (1) ES2662051T3 (enExample)
HU (1) HUE037574T2 (enExample)
MX (1) MX336800B (enExample)
NO (1) NO2424495T3 (enExample)
PL (1) PL2424495T3 (enExample)
PT (1) PT2424495T (enExample)
SI (1) SI2424495T1 (enExample)
WO (1) WO2010126911A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583084C (en) 2003-09-19 2010-12-07 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
EP2564842A1 (en) * 2005-06-01 2013-03-06 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
CA2704473C (en) 2007-11-06 2016-10-04 Edison Pharmaceuticals, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2974482C (en) 2008-10-28 2019-10-29 Bioelectron Technology Corporation High purity alpha tocotrienol quinone and processes for preparing same
NO2424495T3 (enExample) 2009-04-28 2018-06-16
SI2470168T1 (en) * 2009-08-26 2018-05-31 Bioelectron Technology Corporation Procedures for the prevention and treatment of brain ischemia
WO2011082355A1 (en) * 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
EP2642991A1 (en) 2010-11-22 2013-10-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutical method for the treatment of the leber optic
WO2012174286A1 (en) * 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
US20150057363A1 (en) * 2011-07-06 2015-02-26 Guy M. Miller Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
RU2658461C2 (ru) 2012-06-29 2018-06-21 Рауф РЕКИК Ингибиторы ангиотензинпревращающего фермента для лечения нейропатии зрительного нерва или врождённой атрофии зрительного нерва
EP2892515A1 (en) 2012-09-07 2015-07-15 Edison Pharmaceuticals, Inc. Benzoquinone derivatives for treating oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
CN114702406B (zh) 2014-12-16 2025-02-25 Ptc医疗公司 化合物的多晶型和无定形形式
MX2017015566A (es) * 2015-06-05 2018-08-15 Fundacio Hospital Univ Vall Dhebron Institut De Recerca Tratamiento de enfermedades mitocondriales.
EP3390377A1 (en) 2015-12-16 2018-10-24 BioElectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
AU2016369616B2 (en) 2015-12-17 2021-03-25 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
AU2019359381A1 (en) * 2018-10-11 2021-04-29 Imbria Pharmaceuticals, Inc. Compositions and methods for treating and preventing Leber's hereditary optic neuropathy
RU2704013C1 (ru) * 2019-04-18 2019-10-23 ФГБНУ "НИИ глазных болезней" Способ коррекции окислительного стресса при наследственной оптической нейропатии Лебера
CN112385783B (zh) 2020-10-10 2022-07-05 南京农业大学 一种控制炭烤肉中多环芳烃含量的烤制方法
WO2024259130A1 (en) * 2023-06-16 2024-12-19 Ptc Therapeutics, Inc. Methods for increasing vatiquinone plasma exposure with food

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4875564A (enExample) 1972-01-08 1973-10-11
JPS4988862A (enExample) 1972-12-29 1974-08-24
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
JPH0788376B2 (ja) 1986-09-02 1995-09-27 エーザイ株式会社 光学活性α−トコトリエノ−ルの製造方法
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
JP2685785B2 (ja) 1988-03-11 1997-12-03 エーザイ株式会社 光学活性α−トコトリエノールの製造方法
JPH029875A (ja) 1988-03-16 1990-01-12 Bio Ind Kyokai トコフェロール及びトコトリエノールの製造方法
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5157132A (en) 1990-05-18 1992-10-20 Carotech Associates Integrated process for recovery of carotenoids and tocotrienols from oil
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
DE69115990T2 (de) 1990-05-29 1996-05-30 Ocular Res Of Bonton Inc Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
CA2124086A1 (en) 1991-11-22 1993-05-27 Ronald H. Lane Tocotrienols and tocotrienol-like compounds and methods for their use
US5318993A (en) * 1993-04-16 1994-06-07 Bristol-Myers Squibb Company Antihyperlipidemic benzoquinones
EP0708646A1 (en) 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
ES2176354T3 (es) 1994-12-28 2002-12-01 Janssen Pharmaceutica Nv Uso de nebivolol como agente anti-aterogenico.
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
WO1999038859A1 (en) 1998-01-29 1999-08-05 Eastman Chemical Company Methods for separating a tocol from a tocol-containing mixture
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6395915B1 (en) 1999-09-10 2002-05-28 Technikrom, Inc. Method for producing purified tocotrienols and tocopherols using liquid chromatography
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
MY127451A (en) 1999-11-04 2006-12-29 Malaysian Palm Oil Board A method of chromatographic isolation for vitamin e isomers
DE10034233A1 (de) 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
GB0023555D0 (en) * 2000-09-26 2000-11-08 Inst Of Ophthalmology Improvements in and relating to treatments for eye disease
US7034054B2 (en) 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
WO2002047680A2 (en) 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US6838104B2 (en) 2000-12-20 2005-01-04 Archer Daniels Midland Company Process for the production of tocotrienols
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
MXPA04001555A (es) 2001-08-21 2004-10-27 Galileo Pharmaceuticals Inc Composiciones enriquecidas con tocoferol y mejoramiento de sintomas inflamatorios.
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US7078541B2 (en) 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
ATE328283T1 (de) 2002-07-01 2006-06-15 Santhera Pharmaceuticals Ch Screeningverfahren und verbindungen zur behandlung von friedreich ataxia
JP4599292B2 (ja) 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
US7015243B2 (en) * 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
CA2583084C (en) 2003-09-19 2010-12-07 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
US20050074447A1 (en) * 2003-10-01 2005-04-07 Papas Andreas M. Treatment for diabetic microvascular and macrovascular complications
WO2005035491A2 (en) 2003-10-10 2005-04-21 Yasoo Health, Inc. PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND
US8182990B2 (en) 2004-03-18 2012-05-22 Rusk Intellectual Reserve Ag Method for diagnosing or predicting susceptibility to optic neuropathy
DE602004022523D1 (de) 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
ES2532997T3 (es) 2005-04-22 2015-04-06 Elizabeth Stuart Uso de tocotrienoles de vitamina E para la inhibición del patógeno intracelular obligado Chlamydia
EP2564842A1 (en) * 2005-06-01 2013-03-06 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JP2009508867A (ja) 2005-09-15 2009-03-05 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体
CA2850858A1 (en) 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
JP5374162B2 (ja) * 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
CN101610782A (zh) 2007-01-10 2009-12-23 爱迪生药物公司 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱
WO2008157747A1 (en) 2007-06-21 2008-12-24 The Jackson Laboratory Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
US20100209436A1 (en) 2007-07-03 2010-08-19 Andreas Reichert Method for treating diseases related to mitochondrial dysfunction
ES2507078T3 (es) 2007-08-16 2014-10-14 Santen Pharmaceutical Co., Ltd Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad
US8075909B2 (en) 2007-09-04 2011-12-13 University Of Florida Research Foundation, Incorporated Contact lens based bioactive agent delivery system
CA2704473C (en) 2007-11-06 2016-10-04 Edison Pharmaceuticals, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009088572A2 (en) 2008-01-07 2009-07-16 Centocor, Inc. Method of treating erythropoietin hyporesponsive anemias
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
US20110046156A1 (en) 2008-03-05 2011-02-24 Miller Guy M Treatment of hearing and balance impairments with redox-active therapeutics
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2009140382A2 (en) 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2724841A1 (en) 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US8716486B2 (en) 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US20100010100A1 (en) 2008-07-09 2010-01-14 Hinman Andrew W Dermatological compositions with anti-aging and skin even-toning properties
US20100029784A1 (en) 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
JP5731980B2 (ja) 2008-10-09 2015-06-10 ラムズコア， インコーポレイテッド ドライアイ症候群の処置のための組成物および方法
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2974482C (en) 2008-10-28 2019-10-29 Bioelectron Technology Corporation High purity alpha tocotrienol quinone and processes for preparing same
NO2424495T3 (enExample) 2009-04-28 2018-06-16
US20100273892A1 (en) 2009-04-28 2010-10-28 Miller Guy M Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
JP2012525398A (ja) 2009-04-28 2012-10-22 アンペア ライフ サイエンシーズ，インコーポレイテッド 眼科障害を治療するためのトコトリエノールの局所、眼周囲または眼内使用
MX2011013558A (es) 2009-06-25 2012-04-30 Ampere Life Sciences Inc Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos.
SI2470168T1 (en) 2009-08-26 2018-05-31 Bioelectron Technology Corporation Procedures for the prevention and treatment of brain ischemia
WO2011041452A2 (en) 2009-10-01 2011-04-07 Ampere Life Sciences, Inc. Mouse model for identifying compounds for the treatment of oxidative stress
WO2011082355A1 (en) 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011113018A1 (en) 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time
EA201201374A1 (ru) 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
EP2563352A4 (en) 2010-04-27 2013-11-13 Edison Pharmaceuticals Inc FORMULAS FROM CHINESE FOR THE TREATMENT OF EYE DISEASES
US20120101169A1 (en) 2010-07-14 2012-04-26 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
WO2012019032A1 (en) 2010-08-06 2012-02-09 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
US20130345312A1 (en) 2010-08-06 2013-12-26 Orion D. Jankowski Treatment of mitochondrial diseases with naphthoquinones
US20120295985A1 (en) 2010-11-19 2012-11-22 Miller Guy M Methods for improving blood glucose control
WO2012154613A1 (en) 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013006736A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
US20150057363A1 (en) 2011-07-06 2015-02-26 Guy M. Miller Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
EP2892515A1 (en) 2012-09-07 2015-07-15 Edison Pharmaceuticals, Inc. Benzoquinone derivatives for treating oxidative stress disorders
JP6313791B2 (ja) 2013-03-08 2018-04-18 ユニリーバー・ナームローゼ・ベンノートシヤープ 皮膚科学的使用のためのレゾルシノール化合物
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
WO2014194292A1 (en) 2013-05-31 2014-12-04 Edison Pharmaceuticals, Inc. Carboxylic acid derivatives for treatment of oxidative stress disorders

Also Published As

Publication number Publication date
JP2012525399A (ja) 2012-10-22
MX336800B (es) 2016-02-02
US20100273894A1 (en) 2010-10-28
WO2010126911A1 (en) 2010-11-04
US20140039065A1 (en) 2014-02-06
EP2424495B1 (en) 2018-01-17
EA201101575A1 (ru) 2012-04-30
BRPI1013376A2 (pt) 2017-03-21
HUE037574T2 (hu) 2018-09-28
US20170119695A1 (en) 2017-05-04
PL2424495T3 (pl) 2018-06-29
MX2011011309A (es) 2011-11-18
DK2424495T3 (en) 2018-04-30
EA031126B1 (ru) 2018-11-30
JP2015028084A (ja) 2015-02-12
EP3332766A1 (en) 2018-06-13
NO2424495T3 (enExample) 2018-06-16
CA2777479A1 (en) 2010-11-04
ES2662051T3 (es) 2018-04-05
PT2424495T (pt) 2018-03-13
JP2016216506A (ja) 2016-12-22
US9370496B2 (en) 2016-06-21
CA2777479C (en) 2017-10-17
US10195161B2 (en) 2019-02-05
SI2424495T1 (en) 2018-04-30
EP2424495A1 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
BRPI1013376A8 (pt) tratamento de neuropata ótica hereditária de leber e atrofia ótica dominante com quinonas de tocotrienol.
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
WO2009092383A3 (en) Products and methods to prevent infection
IN2012DN00624A (enExample)
WO2009129246A3 (en) Compositions and methods for preparing and using same
MY173616A (en) Compositions and methods for lowering triglycerides
WO2012097213A3 (en) Methods for diagnosing and treating eye-length related disorders
NO20082473L (no) Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
WO2009111576A3 (en) 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2012003474A3 (en) Compositions and methods related to protein a (spa) variants
BR112012002461A2 (pt) composições de vidro e fibras preparadas a partir das mesmas
WO2006048242A3 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
WO2012170947A3 (en) Methods for modulating factor 12 expression
BR112015002464B8 (pt) processo para a preparação de carbamat-benzoxazinona, carbamat-benzoxazinona e uso da carbamat-benzoxazinona
MY150931A (en) Substituted oxazolidinones and their use
WO2009090394A3 (en) Composition containing capsicum for treating a skin disorder
WO2010052575A3 (en) Ngna compositions and methods of use
ATE524488T1 (de) Lysobactinamide
WO2008095122A3 (en) Methods of reducing 15-f2t-isop levels in mammals
WO2013067076A3 (en) Methods and compositions for neuroprotection
UY30042A1 (es) Nuevos derivados de alquilfosfolípidos con citotoxicidad reducida y usos de los mismos.
WO2009158511A8 (en) Factor viii muteins with reduced immunogenicity
BRPI0618496A2 (pt) artigos adesivos e kit de adesivo para dentaduras, bem como método para proporcionar ajuste otomizado das mesmas
BR112012011261A2 (pt) tratamento de infecções microbianas
ATE410443T1 (de) Heterocyclyl-substituierte nonadepsipeptide

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOELECTRON TECHNOLOGY CORPORATION (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]
B25B Requested transfer of rights rejected

Owner name: BIOELECTRON TECHNOLOGY CORPORATION (US)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870200121037 DE 25/09/2020, EM VIRTUDE DO ARQUIVAMENTO (11.20) PUBLICADO NA RPI2594 DE 24/09/2020.